World News | Associated Press | Friday February 12, 2016
Britain's competition authority has fined drug maker GlaxoSmithKline plc 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.
www.ndtv.com